TEW-7197 첫 용량 투여에서 안전성 확인, 용량증대 결정
Oct 21, 2015EVENTSHit 1624
On 14th of Oct. 2014 (13th in USA) SMC reviewed safety of the first cohort of TEW-7197 (NCT02160106) and did not find any drug-related toxicity. The committee recommended a dose escalation to the next level. Three clinical sites in the USA started recruitment of patients with solid tumor for the second cohort.
|Previous||(주)메드팩토의 대주주이자 설립자인 김성진 박사가 공동대표자로 선임|
|Next||ANRT 와 협약|